NewLink Genetics Corp. | Mutual Funds
Mutual Funds that own NewLink Genetics Corp.
Vanguard Total Stock Market Index Fund
715,224
1.92%
28,591
0%
07/31/2018
T Rowe Price Small Cap Value Fund
628,000
1.69%
-203,900
0.02%
06/30/2018
iShares Russell 2000 ETF
594,492
1.6%
-318
0%
09/06/2018
iShares Nasdaq Biotechnology ETF
418,398
1.12%
-5,481
0.01%
09/06/2018
JPMorgan US Small Companies Fund
414,500
1.11%
8,100
0.07%
07/31/2018
Vanguard Extended Market Index Fund
381,345
1.02%
0
0%
07/31/2018
Candriam Equities L - Biotechnology
293,000
0.79%
0
0.07%
07/31/2018
iShares Russell 2000 Value ETF
241,389
0.65%
0
0.01%
09/06/2018
Vanguard Variable Insurance - Small Company Growth Portfolio
195,928
0.53%
195,928
0.03%
06/30/2018
Rhenman & Partners Fund - Healthcare Equity L/S
181,047
0.49%
181,047
0.04%
12/31/2017
| Address |
2503 South Loop Drive
Ames Iowa 50010
United States
|
|
Employees
|
- |
| Website |
http://www.newlinkgenetics.com |
| Updated |
07/08/2019 |
| NewLink Genetics Corp. is a late-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of novel immunotherapeutic products to improve cancer treatment options for patients and physicians. The firm's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a range of oncology indications. |
